Treatment of Postrenal Transplantation Lymphoproliferative Disease Manifesting as Plasmacytoma with Nonmyeloablative Hematopoietic Stem Cell Transplantation from the Same Kidney Donor

American Journal of Hematology

Volumn 74, Issue 4, 2003, Pages 283-286

  Au, W Y ^a   Lie, A K W ^a   Chan, E C ^a   Pang, A ^a   Ma, S K ^a   Choy, C ^a   Kwong, Y L ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Nonmyeloablative hematopoietic stem cell transplantation; Posttransplantation lymphoproliferative disease; Renal transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

AGED; ARTICLE; BLOOD; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY DONOR; LYMPHOPROLIFERATIVE DISEASE; MALE; NOSE DISEASE; PLASMACYTOMA; PRIORITY JOURNAL; RELAPSE;

AGED; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; NOSE NEOPLASMS; PLASMACYTOMA; TISSUE DONORS;

EID: 0344012596     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10417     Document Type: Article

References (9)

1. Swinnen L. Post-transplant lymphoproliferative disorders: implications for acquired immunodeficiency syndrome-associated malignancies. J Natl Cancer Inst Monogr 2001;28:38-43.
2. Au WY, Lo CM, Hawkins BR, Ma ES, Lie AK, Kwong YL. Evans' syndrome complicating chronic graft versus host disease after cadaveric liver transplantation. Transplantation 2001;72: 527-528.
3. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997;14:8-14.
4. Wagner HJ, Fischer L, Jabs WJ. Holbe M, Pethig K, Bucsky P. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 2002;74: 656-664.
5. Dey B, Sykes M, Spitzer TR. Outcomes of recipients of both bone marrow and solid organ transplants. A review. Medicine 1998;77: 355-369.
6. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002;99:2592-2598.
7. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneiccytotoxic T cells. Lancet 2002; 360:436-442.
8. Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002;20:1295-1303.
9. Au WY, Kwong YL, Lie AK, Ma SK, Liang R. Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol 1999;17:45-52.